In vitro tests for Drug Hypersensitivity Reactions. An ENDA/EAACI Drug Allergy Interest Group Position Paper

Allergy

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) 

C Mayorga^1,2, 

G Celik³, 

P Rouzaire⁴, 

P Whitaker⁵, 

P Bonadonna⁶, 

J Rodrigues Cernadas⁷, 

A Vultaggio⁸, 

K Brockow⁹, 

JC Caubet¹⁰, 

J Makowska¹¹, 

A Nakonechna¹², 

A Romano¹³, 

MI Montañez¹⁴, 

JJ Laguna¹⁵, 

G Zanoni¹⁶, 

JL Gueant¹⁷, 

H Oude Elberink¹⁸, 

J Fernandez¹⁹, 

S Viel²⁰, 

P Demoly²¹, 

MJ Torres^2,* and

In vitro tests for Drug Allergy Task Force of EAACI Drug Interest Group

Position Paper

Summary

Drug hypersensitivity reactions (DHR) are a matter of great concern, both for outpatient and in hospital care. The evaluation of these patients is complex, since in vivo tests have suboptimal sensitivity and can be time-consuming, expensive and potentially risky, especially drug provocation tests. There are several currently available in vitro methods that can be classified into two main groups: those that help to characterize the active phase of the reaction and those that help to identify the culprit drug.

Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure

Review

Advances in Therapy

pp 1-21

Open Access

John D. Sheppard

, Timothy L. Comstock, Megan E. Cavet

Abstract

Corticosteroids are a mainstay therapeutic option for the treatment of ocular inflammation. However, safety remains a concern for clinicians, particularly with long-term use. Though highly effective at suppressing inflammatory and allergic responses, topical ophthalmic corticosteroids carry an inherent risk of side effects, including elevated intraocular pressure (IOP), a risk factor for the development of glaucoma.

Environmental Pollution: An Under-recognized Threat to Children’s Health, Especially in Low- and Middle-Income Countries

BRIEF COMMUNICATION

VOLUME 124 | ISSUE 3 | MARCH 2016

William A. Suk,1 Hamid Ahanchian,2 Kwadwo Ansong Asante,3 David O. Carpenter,4 Fernando Diaz-Barriga,5 Eun-Hee Ha,6Xia Huo,7 Malcolm King,8 Mathuros Ruchirawat,9 Emerson R. da Silva,10 Leith Sly,11 Peter D. Sly,11 Renato T. Stein,12 Martin van den Berg,13 Heather Zar,14 and Philip J. Landrigan15

Author Affiliations open

 PDF Version (132 KB)

• Summary
• About This Article

• 
  
• Exposures to environmental pollutants during windows of developmental vulnerability in early life can cause disease and death in infancy and childhood as well as chronic, non-communicable diseases that may manifest at any point across the life span. Patterns of pollution and pollution-related disease change as countries move through economic development.

The definition, diagnostic testing and management of chronic inducible urticarias – update and revision of the EAACI/GA2LEN/EDF/UNEV 2009 consensus panel recommendations

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

1. M. Magerl¹, 
2. S. Altrichter¹, 
3. E. Borzova², 
4. A. Giménez-Arnau⁴, 
5. C. E. H. Grattan³, 
6. F. Lawlor³, 
7. P. Mathelier-Fusade⁵, 
8. R. Y. Meshkova⁶, 
9. T. Zuberbier¹, 
10. M. Metz¹and
11. M. Maurer^1,

Abstract

These recommendations for the definition, diagnosis and management of chronic inducible urticaria (CIndU) extend, revise and update our previous consensus report on physical urticarias and cholinergic urticaria (1)

A Case of Pranlukast-Induced Anaphylactic Shock

Case Report  Open Access           Allergy Asthma Immunol Res. 2016 May;8(3):276-278. English. Sujeong Kim and Jong-Myung Lee Abstract Leukotriene receptor antagonists, which are generally considered safe with a few  adverse drug reactions, are increasingly used in the treatment of various allergic  diseases, including asthma and allergic rhinitis. Although a few anaphylactic  reactions to montelukast have been reported worldwide, there is still a lack of  reports about severe adverse drug reactions associated with pranlukast. Here, we  report a case of severe hypersensitivity reaction associated with pranlukast.

Angiopoietin-2 concentration in serum is associated with severe asthma phenotype

RESEARCH

OPEN ACCESS

• Joanna S. MakowskaEmail author, 
• Małgorzata Cieślak, 
• Marzanna Jarzębska, 
• Anna Lewandowska-Polak and 
• Marek L. Kowalski

Allergy, Asthma & Clinical Immunology201612:8

DOI: 10.1186/s13223-016-0112-6

Abstract

Background

Several proangiogenic molecules have been implicated in the pathogenies of asthmatic inflammation and remodeling. The aim of the study was to compare the concentration of proangiogenic factors in the sera of asthmatic patients and in healthy subjects (HS), and to refer the concentrations to both clinical and inflammatory markers of the disease severity.

Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis

Cochrane Database Syst Rev. 2015 Jun 1;6:CD009566. doi: 10.1002/14651858.CD009566.pub2.

Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A.

Abstract

Background

Seasonal/perennial allergic conjunctivitis is the most common allergic conjunctivitis, usually with acute manifestations when a person is exposed to allergens and with typical signs and symptoms including itching, redness, and tearing. The clinical signs and symptoms of allergic conjunctivitis are mediated by the release of histamine by mast cells. Histamine antagonists (also called antihistamines) inhibit the action of histamine by blocking histamine H1 receptors, antagonising the vasoconstrictor, and to a lesser extent, the vasodilator effects of histamine. Mast cell stabilisers inhibit degranulation and consequently the release of histamine by interrupting the normal chain of intracellular signals.

Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy?

RESEARCH

OPEN ACCESS

• Sten Dreborg, 
• Xia Wen, 
• Laura Kim, 
• Gina Tsai, 
• Immaculate Nevis, 
• Ryan Potts, 
• Jack Chiu, 
• Arunmozhi Dominic and 
• Harold KimEmail author

Allergy, Asthma & Clinical Immunology201612:11

DOI: 10.1186/s13223-016-0110-8

Abstract

Background

Food allergy is the most common cause of anaphylaxis in children. Intramuscular delivery of epinephrine auto-injectors (EAI) is the standard of care for the treatment of anaphylaxis. We examined if children and adolescents at risk of anaphylaxis weighing 15–30 kg and >30 kg would receive epinephrine into the intramuscular space with the currently available EAI in North America and Europe.

Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study

Rainer Reiber, 

Martina Keller, 

Winfried Keller, 

Hendrik Wolf

, 

Jörg Schnitker and 

Eike Wüstenberg

Clinical and Translational Allergy20166:9

DOI: 10.1186/s13601-016-0097-8

Abstract

Background

The majority of allergic patients are poly-sensitized. For causal treatment by allergy immunotherapy (AIT) a single or few allergen products containing the clinically most relevant allergens are applied, but few data on tolerability of multiple application of AIT is available. The aim of our study was to investigate safety and tolerability in patients who started treatment by sublingual immunotherapy (SLIT) with the standardised SQ® grass SLIT-tablet and were treated with concomitant AIT products.

Hydrolysed formula and risk of allergic or autoimmune disease: systematic review and meta-analysis

BMJ 2016; 352 doi: http://dx.doi.org/10.1136/bmj.i974 (Published 08 March 2016)

Cite this as: BMJ 2016;352:i974

1. Robert J Boyle, senior lecturer in paediatric allergy1, 
2. Despo Ierodiakonou, postdoctoral research fellow1 2, 
3. Tasnia Khan, medical student1, 
4. Jennifer Chivinge, medical student1, 
5. Zoe Robinson, medical student1, 
6. Natalie Geoghegan, medical student1, 
7. Katharine Jarrold, medical student1, 
8. Thalia Afxentiou, postgraduate student1, 
9. Tim Reeves, librarian2, 
10. Sergio Cunha, postdoctoral research associate3, 
11. Marialena Trivella, senior medical statistician4, 
12. Vanessa Garcia-Larsen, postdoctoral research fellow2, 
13. Jo Leonardi-Bee, professor of medical statistics5
14. 
    

Abstract

Objective To determine whether feeding infants with hydrolysed formula reduces their risk of allergic or autoimmune disease.

Design Systematic review and meta-analysis, as part of a series of systematic reviews commissioned by the UK Food Standards Agency to inform guidelines on infant feeding. Two authors selected studies by consensus, independently extracted data, and assessed the quality of included studies using the Cochrane risk of bias tool.

Recurrent wheezing in children

 
• Vol 5, No 1 (January 2016) 

Authors: Laura Tenero, Michele Piazza, Giorgio Piacentini

Abstract: Recurrent wheezing have a significant morbidity and it’s estimated that about one third of schoolage children manifest the symptom during the first 5 years of life. Proper identification of children at risk of developing asthma at school age may predict long-term outcomes and improve treatment and preventive approach, but the possibility to identify these children at preschool age remains limited.